Meclofenamic Acid Veterinary Grade API (model designation MCA-VET-API) is a fenamate-class non-steroidal anti-inflammatory active pharmaceutical ingredient supplied as a white to off-white crystalline powder for further processing into tablets, capsules, injectable solutions, oral powders, granules, premixes, and oral solutions. The free acid corresponds to the molecular formula C14H11Cl2NO2 and molar mass 296.15 g/mol; the sodium salt, meclofenamate sodium, is supplied as a water-soluble alternative with molar mass 318.13 g/mol for the anhydrous form. The API is manufactured under ICH Q7 good manufacturing practice conditions for active pharmaceutical ingredients. A Type II drug master file supports the veterinary marketing authorization, and each batch is released against a certificate of analysis that includes appearance, infrared identification, assay, related substances, residual solvents, water content, residue on ignition, elemental impurities, and particle size distribution. The API is controlled for mutagenic impurities according to current ICH M7 principles, and a nitrosamine risk assessment is documented for process-derived secondary amine sources.

Physical Form, Salt Stoichiometry, and Pharmacopoeial Identity

The free acid and sodium salt differ in handling behavior. The free acid is a weak carboxylic acid with pH-dependent aqueous solubility; it requires particle size reduction for immediate-release solid dosage forms because dissolution from coarse particles is slow under acidic gastric conditions. The sodium salt dissolves readily in water and is therefore preferred for injectable and oral solution formulations, but it is more hygroscopic and must be stored in sealed containers below 25 °C and 60% RH. Infrared identification is matched against a current pharmacopoeial reference standard; X-ray powder diffraction is used to verify the crystalline form. The crystalline habit is typically acicular, which can produce low bulk density and poor powder flow. Compaction studies on a rotary tablet press show that the free acid may exhibit sticking and picking at punch-face temperatures above 35 °C; however, published data for this specific API is limited, and a compaction simulator should be used to determine Heckel yield pressure before final tooling selection.

Solid-state characterization of meclofenamic acid by differential scanning calorimetry shows a sharp melting endotherm; polymorph screening is required because the API can exhibit multiple crystalline habits. X-ray powder diffraction is used to verify polymorphic form after micronization. Milling changes surface crystallinity and may generate amorphous content; at high amorphous fractions, moisture uptake increases and dissolution can become variable. Thermal analysis of the free acid should be supplemented by dynamic vapor sorption at 25 °C and 0–90% RH to define storage and granulation moisture limits. The sodium salt is more hygroscopic than the free acid and should be sampled under dry nitrogen where headspace humidity exceeds 60% RH.

Representative release specifications for the veterinary-grade API are listed in Table 1. The acceptance limits are typical for a pharmacopoeial-grade material; batch-specific values follow the current pharmacopoeial monograph and the filed drug master file.

Particle size distribution is determined by laser diffraction according to ISO 13320. The micronized grade is jet-milled under nitrogen to D90 ≤10 µm; the standard grade is pin-milled to D90 ≤150 µm. Particle size reduction increases the specific surface area and improves dissolution, but it also increases electrostatic charging and moisture uptake. Milled material is therefore equilibrated in a controlled environment at 25 °C and 40% RH for 24 h before blending. Residual solvent control follows current ICH Q3C Option 1 limits, and the preferred crystallization solvent system is selected to avoid Class 1 solvents. Headspace gas chromatography is used for release testing. Elemental impurities are controlled according to ICH Q3D for the veterinary route of administration; the parenteral grade requires a lower permitted daily exposure for cadmium, lead, arsenic, and mercury than the oral grade.

What Limits Direct Compression of Meclofenamic Acid Granules?

Direct compression of meclofenamic acid is constrained by low bulk density, acicular particle shape, and high dose fraction. When the API fraction exceeds 40% w/w in a tablet core, blend segregation and weight variability may occur on rotary presses at turret speeds above 60 rpm. Wet granulation in a high-shear mixer or twin-screw granulator is therefore preferred for high-load tablets. A typical granulation fluid is purified water containing povidone K30 at 2% w/w to 5% w/w of the dry granulate mass. The wet mass is passed through a 1.0 mm screen and dried in a fluid-bed dryer to a final moisture content of 1.5% w/w to 2.5% w/w. Magnesium stearate is added at 0.25% w/w to 0.75% w/w; lubrication above 1.0% w/w can retard dissolution of the hydrophobic free acid. Tablet hardness is controlled between 5 kp and 12 kp, and disintegration is tested according to USP 701. Dissolution testing for immediate-release tablets is conducted using USP 711 apparatus II at 50 rpm unless a species-specific veterinary monograph specifies otherwise.

Capsule filling uses the same granulated or milled blend. Fill weight variability is controlled below 3% RSD on an automatic tamping-pin capsule machine. Powder segregation of the free acid is reduced by matching its particle size to filler excipients; the standard grade with D90 ≤150 µm is acceptable for granules, while the micronized grade with D90 ≤10 µm is used for direct-fill formulations containing poorly compressible diluents. For immediate-release tablets, dissolution testing in 900 mL of pH 6.8 phosphate buffer with 0.5% w/v sodium lauryl sulfate is often used during development; however, the final method must reflect the target species gastrointestinal conditions. A dissolution specification of Q ≥80% in 45 min is commonly proposed for poorly soluble weak acids, but published data for this specific formulation configuration is limited. Published data for this specific API in direct compression is limited; formulators should determine Heckel yield pressure, compactibility, and ejection force on a compaction simulator before final compression parameters are fixed.

Injectable-grade meclofenamate sodium is dissolved in Water for Injection at a concentration equivalent to 20 mg/mL to 50 mg/mL of meclofenamic acid, depending on the target species and dosing volume. The solution is adjusted to pH 7.4–8.2 with sodium hydroxide or tromethamine; phosphate buffers may be used provided no precipitation occurs during cold storage. The bulk solution is filtered through a 0.22 µm sterilizing-grade membrane and filled into Type I glass vials. Terminal sterilization by autoclaving at 121 °C for 15 min is used only where pilot-scale thermal cycling confirms that related substances and pH remain within specification; if heat-labile impurities or pH drift are observed, aseptic filtration is used instead. The free acid form is not suitable for aqueous injection because its low water solubility produces particulate matter on dilution. Antioxidants such as sodium metabisulfite at 0.1% w/v are added only if supported by stress oxidation data; otherwise the headspace is blanketed with nitrogen. Endotoxin control is maintained per USP 85, with a limit of <0.5 EU/mg for the parenteral API. Filter compatibility studies are required because meclofenamate sodium solutions may extract leachables from polyethersulfone at low pH; process hold times are limited to reduce oxidative discoloration and related substance formation. Compatibility with polyvinyl chloride infusion containers has not been fully characterized; published data for this specific configuration is limited. The use of inline filters in veterinary administration sets should be confirmed by recovery studies because binding of the active to nylon or polyethersulfone membranes may occur at low concentrations.

When Meclofenamic Acid Replaces Phenylbutazone in Equine Formulations

Meclofenamic acid belongs to the fenamate class, whereas phenylbutazone is a pyrazolidinedione and flunixin is an aminonicotinic acid derivative. All three inhibit cyclooxygenase, but their species-specific residue depletion, protein binding, and regulatory acceptance differ. In equine practice, meclofenamic acid has been used in oral granule formulations; however, published pharmacokinetic data for modern formulation configurations is limited, and withdrawal periods must be established under current regional residue guidelines such as Commission Regulation (EU) No 37/2010 where applicable. Substitution on a milligram-per-kilogram basis is not directly equivalent because elimination half-life, volume of distribution, and active metabolite profiles differ among fenamates, pyrazolidinediones, and aminonicotinic acid derivatives. Product selection should not rely solely on in vitro COX inhibition values; comparative in vivo potency must be confirmed in the target species under the intended dosing schedule.

Compared with phenylbutazone, meclofenamic acid offers a sodium salt option that improves aqueous solubility for liquid and injectable dosage forms. Flunixin is supplied as the meglumine salt for injectable use; meloxicam is available as a COX-2-preferential agent. Meclofenamic acid is considered a non-selective cyclooxygenase inhibitor. Published data for comparative potency against canine or equine COX isoforms is limited, and regulatory maximum residue limits for food-producing species are not automatically transferable from one NSAID to another.

For oral powders, granules, and premixes, the API is adsorbed onto a feed-compatible carrier such as lactose monohydrate, corn starch, or calcium carbonate. Premix homogeneity is assessed by taking 10 thief samples across the blender and accepting a relative standard deviation below 5%. The standard particle size with D90 ≤150 µm is acceptable for meal feeds, but pelleted feeds require granulation to reduce dust and improve flow. Bulk density is controlled between 0.45 g/mL and 0.65 g/mL for consistent volumetric dosing into feed mills. Oral solutions are prepared from the sodium salt in purified water with a preservative system validated according to USP 51. These solutions require pH control above the precipitation threshold of the free acid; if the pH falls below 6.5, visible precipitation can occur. Glycerin or propylene glycol may be added as a cosolvent at 10% v/v to 20% v/v, but the final formulation must be validated for palatability and dose uniformity in the target species.

Granule production by fluid-bed top-spray coating onto sucrose or microcrystalline cellulose spheres is used when controlled release is required. The spray suspension contains meclofenamic acid, a binder, and a suspending agent; the product temperature is maintained below 40 °C to avoid particle sticking. Coated granules are screened through a 1.25 mm sieve and filled into sachets or bulk containers. Blend uniformity is verified using near-infrared spectroscopy where method validation follows current pharmacopoeial guidance. Premixes containing meclofenamic acid should be protected from direct sunlight and high humidity; stability in pelleted feed is assessed by assay after 3 months at 25 °C/60% RH and 6 weeks at 40 °C/75% RH. Published feed stability data for this specific molecule is limited; batch-specific studies are required.

Residue Depletion and Oxidative Incompatibility Are Separate Control Problems

Long-term stability is monitored according to current VICH stability guidance for veterinary drug substances. Bulk API is stored in sealed double polyethylene bags inside a fiber drum, protected from light and maintained below 25 °C and 60% RH. The free acid is incompatible with strong oxidizing agents, and wet granulation with highly alkaline solutions can form salts with altered dissolution behavior. Contact with iron or copper salts should be avoided during solution processing because metal-catalyzed oxidative discoloration may increase related substances. For food-producing species, residue depletion studies must be conducted according to regional requirements; documentation for withdrawal periods is not transferable from one formulation to another. Nitrosamine risk assessments are conducted according to ICH M7 and the current regional guidance for veterinary APIs, with confirmatory testing where process-derived secondary amines are present.